BNP/CALL/ELI LILLY & CO/1000/0.1/19.12.25 | Market Closed - Boerse Frankfurt Warrants 20:50:30 17/05/2024 BST | ||
| 7 EUR | -0.43% |
|
| Current month | -10.76% | ||
| 1 month | -1.54% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 7.05 | +0.28% |
| 16/05/24 | 7.03 | -6.02% |
| 15/05/24 | 7.48 | +12.31% |
| 14/05/24 | 6.66 | +1.83% |
| 13/05/24 | 6.54 | -2.24% |
Real-time Boerse Frankfurt Warrants
Last update May 17, 2024 at 08:50 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PC5FBU |
| ISIN | DE000PC5FBU2 |
| Date issued | 21/02/2024 |
| Strike | 1,000 $ |
| Maturity | 19/12/2025 (579 Days) |
| Parity | 10 : 1 |
| Emission price | 7.12 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.93 € |
|---|---|
| Lowest since issue | 5.6 € |
| Spread | 0.02 € |
| Spread % | 0.28% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
770
USD
Average target price
850.4
USD
Spread / Average Target
+10.44%
- Stock Market
- Warrants
- Warrant
